Figure 5: Antagonist peptide protects and rescues mice from superantigen-induced lethal shock. The protective effect was not specific to the BALB/c mouse strain. A/J mice were also protected by ...

Superantigen-induced death of the innate-like B cells, B1 cell and marginal zone B cells, can result in long lasting supraclonal defects in the repertoire and functional defects in immune ...

Researchers have stated that SARS-CoV-2 manifests several biological and clinical consequences of a superantigen. Therefore, a new study published in the journal Pathogens has focussed on SARS-CoV ...

A detailed look at the spike protein of the SARS-CoV-2 virus and the protein coded for by the mRNA vaccine reveals the presence of a “superantigen” motif. This unique sequence is not present ...

"The function of a superantigen is to 'mess' with the immune system," says Patrick Schlievert, Ph.D., UI professor and chair of microbiology at the UI Carver College of Medicine. "Our study shows ...

Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations. Twenty-one patients (age ...

The key ingredient in the recipe that make staphylococcus and streptococcus infections so dangerous? Superantigen toxins. A new study from The Hebrew University of Jerusalem, twenty years in the ...

One example of a superantigen is staphylococcal enterotoxin C2 (SEC2), which is produced by a type of bacteria. A mutant of SEC2, called ST-4, has been constructed that can activate cytotoxic T ...

In a normal immune response, only about 0.001 % to 0.01 % of all T cells are activated. But a superantigen kicks off an entirely different process. Superantigens are not processed by the ...

Tumour Targeted Superantigen therapy is a novel form of cancer therapy. The principle involves targeting the superantigen with subsequent activation of cytotoxic T cells in tumor tissue. ABR214936 is ...

The underlying T-cell associated mechanism is described by researchers in a new study published on the preprint server bioRxiv* in November 2020, as a response to superantigen activation.

Biotech company NeoTXis' Tumor Targeted Superantigen (TTS) technology works to kill cancer cells in a way that no other available cancer treatment can. Two genetically engineered T Cells (light ...